ERP-Based Research on the Modulation of Remimazolam on Working Memory and Brain Network Mechanisms in Glioma Patients

Inclusion criteria

A. Healthy brain group:

• Aged 18-65 years;

• Native speakers of Chinese;

• Right-handed; ④ Normal vision or corrected vision; ⑤ Healthy brain patient population scheduled for non-neurosurgical operations and anesthesia B. Glioma brain group
• Aged 18-65 years old;

• Native speakers of Chinese;

• Right-handed; ④ ASA physical status I-II;

• Normal vision or corrected vision;

• Patients with supratentorial glioma who have primary unilateral space-occupying lesions confirmed by CT/MRI and require surgery and anesthesia.

Exclusion criteria

A. Healthy brain group:

• Allergic to remimazolam or with contraindications to remimazolam (myasthenia gravis, schizophrenia, severe depressive state);

• History of drug abuse or alcoholism;

• History of mental or neurological diseases that prevent cooperation in completing the trial; ④ Pregnant or lactating women;

• Score of mini-mental state examination (MMSE) < 27; ⑥ Past history of intracranial diseases or intracranial surgery

B. Glioma brain group:

• Receiving sedative treatment within 72 hours prior to the study;

• Destruction of cerebral structural integrity such as open head injury or cerebral parenchyma resection;

• Preoperative elevated intracranial pressure requiring mannitol or other intracranial pressure-lowering treatments, or preoperative radiotherapy and chemotherapy;

• History of drug abuse or alcoholism;

• Pregnant or lactating women; ⑥ Mini-Mental State Examination (MMSE) score < 27; ⑦ History of allergic reaction to remimazolam or having contraindications to remimazolam. Remimazolam is a national controlled drug with addictive properties and must be used under the guidance of a doctor; ⑧ Those with other mental or neurological diseases who are unable to cooperate in completing the trial; ⑨ Unsuitable for participating in this study due to other reasons.